4,4”-Dibromo-p-terphenyl | CAS:17788-94-2

We serve 4,4”-Dibromo-p-terphenyl CAS:17788-94-2 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
4,4''-Dibromo-p-terphenyl

Chemical Name:4,4''-Dibromo-p-terphenyl
CAS.NO:17788-94-2
Synonyms:4,4''-dibromoterphenyl
4,4''-Dibromo-1,1':4',1''-terphenyl
4,4''-DibroMo-p-terphenyl
4,4'-dibromo-p-terphenyl
4,4''-Dibrom-p-terphenyl
DBTP
Molecular Formula:C18H12Br2
Molecular Weight:388.09600
 
Physical and Chemical Properties:
Density:1.562
Melting point:315ºC
Boiling point:411.2ºC
Flash point:236.9ºC
Index of Refraction:1.639
 
Specification:
Appearance:Yellow crystalline powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates



Contact us for information like 4,4”-Dibromo-p-terphenyl chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,DBTP physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,4,4”-dibromoterphenyl Use and application,4,4”-DibroMo-p-terphenyl technical grade,usp/ep/jp grade.


Related News: Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.diethoxy-methyl-(3,3,3-trifluoropropyl)silane manufacturer Beta Bionics, Inc. recently announced it has received Breakthrough Device designation from the US FDA for its investigational iLet Bionic Pancreas System.4-Chloro-3-fluorobenzoic acid supplier The downstream industry of the pharmaceutical intermediate industry is mainly the production of APIs, and the relationship between APIs and preparations is in the upstream and downstream industry chain. The consumer demand for downstream preparations will directly affect the demand for APIs.Ethyl acetoacetate vendor Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.Over the past twelve months, the collaboration team has worked to optimize its processes for making T cells from iPSCs, and has now shown the production of pure T-lymphocytes consisting of both CD8+ and CD4+ T cells having a global gene expression profile that is highly-similar to primary T cells based on a principal component analysis.